A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
-
REGULATORY MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed
November 9, 2021
-
REGULATORY Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
November 8, 2021
-
REGULATORY Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
-
BUSINESS New EA Pharma CEO Eager to Put Company Back on Growth Track by Boosting Its Sales Strength
November 5, 2021
-
REGULATORY Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
-
BUSINESS 7 Major Japan Drug Makers Net Two-Digit Growth in Combined H1 Sales on Flagship Brands, Upfront Income
November 4, 2021
-
BUSINESS Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
-
BUSINESS Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
-
BUSINESS Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
-
BUSINESS Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
-
ORGANIZATION PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
-
REGULATORY Late-Phase Trials with Overseas Participation Pragmatic Approach for Japan-Made COVID-19 Vaccine Development: PMDA Director
October 29, 2021
-
REGULATORY Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
-
BUSINESS Sumitomo Dainippon to Speed Up Development of CNS Blockbuster Hopeful through Otsuka Alliance
October 28, 2021
-
BUSINESS CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
-
BUSINESS Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
-
COMMENTARY SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
October 26, 2021
-
BUSINESS KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
-
ORGANIZATION Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…